Birth cohort-specific trends of sun-related behaviors among individuals from an international consortium of melanoma-prone families.

High-risk families Melanoma Skin Cancer Sun exposure Sun-related behaviors Sunbed Sunburn Sunscreen use Trends

Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
23 04 2021
Historique:
received: 22 10 2020
accepted: 10 02 2021
entrez: 23 4 2021
pubmed: 24 4 2021
medline: 22 5 2021
Statut: epublish

Résumé

Individuals from melanoma-prone families have similar or reduced sun-protective behaviors compared to the general population. Studies on trends in sun-related behaviors have been temporally and geographically limited. Individuals from an international consortium of melanoma-prone families (GenoMEL) were retrospectively asked about sunscreen use, sun exposure (time spent outside), sunburns, and sunbed use at several timepoints over their lifetime. Generalized linear mixed models were used to examine the association between these outcomes and birth cohort defined by decade spans, after adjusting for covariates. A total of 2407 participants from 547 families across 17 centers were analyzed. Sunscreen use increased across subsequent birth cohorts, and although the likelihood of sunburns increased until the 1950s birth cohort, it decreased thereafter. Average sun exposure did not change across the birth cohorts, and the likelihood of sunbed use increased in more recent birth cohorts. We generally did not find any differences in sun-related behavior when comparing melanoma cases to non-cases. Melanoma cases had increased sunscreen use, decreased sun exposure, and decreased odds of sunburn and sunbed use after melanoma diagnosis compared to before diagnosis. Although sunscreen use has increased and the likelihood of sunburns has decreased in more recent birth cohorts, individuals in melanoma-prone families have not reduced their overall sun exposure and had an increased likelihood of sunbed use in more recent birth cohorts. These observations demonstrate partial improvements in melanoma prevention and suggest that additional intervention strategies may be needed to achieve optimal sun-protective behavior in melanoma-prone families.

Sections du résumé

BACKGROUND
Individuals from melanoma-prone families have similar or reduced sun-protective behaviors compared to the general population. Studies on trends in sun-related behaviors have been temporally and geographically limited.
METHODS
Individuals from an international consortium of melanoma-prone families (GenoMEL) were retrospectively asked about sunscreen use, sun exposure (time spent outside), sunburns, and sunbed use at several timepoints over their lifetime. Generalized linear mixed models were used to examine the association between these outcomes and birth cohort defined by decade spans, after adjusting for covariates.
RESULTS
A total of 2407 participants from 547 families across 17 centers were analyzed. Sunscreen use increased across subsequent birth cohorts, and although the likelihood of sunburns increased until the 1950s birth cohort, it decreased thereafter. Average sun exposure did not change across the birth cohorts, and the likelihood of sunbed use increased in more recent birth cohorts. We generally did not find any differences in sun-related behavior when comparing melanoma cases to non-cases. Melanoma cases had increased sunscreen use, decreased sun exposure, and decreased odds of sunburn and sunbed use after melanoma diagnosis compared to before diagnosis.
CONCLUSIONS
Although sunscreen use has increased and the likelihood of sunburns has decreased in more recent birth cohorts, individuals in melanoma-prone families have not reduced their overall sun exposure and had an increased likelihood of sunbed use in more recent birth cohorts. These observations demonstrate partial improvements in melanoma prevention and suggest that additional intervention strategies may be needed to achieve optimal sun-protective behavior in melanoma-prone families.

Identifiants

pubmed: 33888076
doi: 10.1186/s12889-021-10424-5
pii: 10.1186/s12889-021-10424-5
pmc: PMC8063451
doi:

Substances chimiques

Sunscreening Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

692

Subventions

Organisme : Sixth Framework Programme
ID : LSH-CT-2006-018702
Organisme : Cancer Research UK Programme Award
ID : C588/A4994
Organisme : Cancer Research UK Programme Award
ID : C588/ A10589
Organisme : United Kingdom Clinical Research Collaboration (GB)
ID : C8216/A6129
Organisme : NIH HHS
ID : R01 CA83115
Pays : United States
Organisme : National Health and Medical Research Council of Australia
ID : NHMRC 107359, 402761, 633004, 566946, 211172, 1093017, 1147843
Organisme : Cancer Council NSW
ID : project grant 77/00, 06/10
Organisme : Cancer Institute NSW
ID : CINSW 05/TPG/1-01, 10/TPG/1-02], 15/CDF/1-14
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : 2007/04313-2
Organisme : H2020 European Research Council ()
ID : ERC-2011-294576
Organisme : Spanish Fondo de Investigaciones Sanitarias
ID : PI15/00716, PI15/00956
Organisme : Catalan Government, Spain
ID : AGAUR 2014_SGR_603
Organisme : Fundació la Marató de TV3
ID : 201331-30
Organisme : Fundación Científica Asociación Española Contra el Cáncer
ID : GCB15152978SOEN
Organisme : Italian Ministry of Health
ID : RF-2016-02362288
Organisme : Consejo Nacional de Ciencia y Tecnología
ID : 152256/158706

Références

Br J Dermatol. 2020 Apr;182(4):849-859
pubmed: 31381131
Eur J Cancer. 2005 Jan;41(1):45-60
pubmed: 15617990
Int J Cancer. 2002 Jan 1;97(1):90-5
pubmed: 11774248
Eur J Cancer. 2019 Sep;118:149-155
pubmed: 31349135
Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):142-5
pubmed: 16434600
Am J Prev Med. 2016 Sep;51(3):e77-85
pubmed: 27067306
Br J Dermatol. 2015 Feb;172(2):475-83
pubmed: 25279754
Am J Public Health. 2020 Jun;110(6):823-828
pubmed: 32298165
Br J Dermatol. 2013 Jan;168(1):154-61
pubmed: 23039760
MMWR Morb Mortal Wkly Rep. 2012 May 11;61(18):317-22
pubmed: 22572977
J Eur Acad Dermatol Venereol. 2018 Feb;32(2):225-235
pubmed: 28573745
PLoS Med. 2019 Oct 8;16(10):e1002932
pubmed: 31593565
Eur J Cancer. 2012 Nov;48(16):3052-62
pubmed: 22726816
World J Surg. 1992 Mar-Apr;16(2):157-65
pubmed: 1561794
J Community Health. 2018 Oct;43(5):993-1001
pubmed: 29623503
Cancer Causes Control. 2007 Apr;18(3):295-304
pubmed: 17206532
J Am Acad Dermatol. 2017 Jun;76(6):1191-1193
pubmed: 28522044
Acta Derm Venereol. 2017 Nov 15;97(10):1202-1205
pubmed: 28815267
Skinmed. 2018 Dec 21;16(6):379-383
pubmed: 30575505
Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):169-77
pubmed: 25587110
Australas J Dermatol. 2017 May;58(2):111-116
pubmed: 26776445
Prog Biophys Mol Biol. 2011 Dec;107(3):349-55
pubmed: 21907230
Psychol Res Behav Manag. 2013 Dec 20;7:9-18
pubmed: 24379732
Pediatr Dermatol. 2019 May;36(3):317-323
pubmed: 30895676
JCO Glob Oncol. 2020 Apr;6:575-582
pubmed: 32293941
Qual Health Res. 2012 Jul;22(7):934-45
pubmed: 22645220
Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2427-32
pubmed: 16214927
Eur J Public Health. 2012 Jun;22(3):408-12
pubmed: 22094579
J Am Acad Dermatol. 2016 Aug;75(2):371-379.e5
pubmed: 27198078
Cancer Causes Control. 2001 Jan;12(1):69-82
pubmed: 11227927
J Epidemiol. 2018 Jan 5;28(1):27-33
pubmed: 29176271
Int J Cancer. 2013 Jan 15;132(2):385-400
pubmed: 22532371
Aust N Z J Public Health. 2016 Oct;40(5):468-473
pubmed: 27523880
Cancer Causes Control. 2004 Nov;15(9):957-65
pubmed: 15577298
Aust N Z J Public Health. 2013 Feb;37(1):63-9
pubmed: 23379808
Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):607-613
pubmed: 28254810
J Adolesc Health. 2012 Mar;50(3):304-7
pubmed: 22325137
Ecancermedicalscience. 2020 Mar 05;14:1017
pubmed: 32256700

Auteurs

John Charles A Lacson (JCA)

Department of Cancer Epidemiology, Division of Population Science, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Dr., MRC 213, Tampa, FL, 33612, USA.

Shawn A Zamani (SA)

Department of Cancer Epidemiology, Division of Population Science, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Dr., MRC 213, Tampa, FL, 33612, USA.
Medical Research Council - Cancer Unit, Division of Clinical Medicine, University of Cambridge, Cambridge, Cambridgeshire, UK.

Luis Alberto Ribeiro Froes (LAR)

Department of Pathology, School of Medicine, Universidade de São Paulo (USP), São Paulo, SP, Brazil.

Nandita Mitra (N)

Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA.

Lu Qian (L)

SWOG Statistics and Data Management Center, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Scarlet H Doyle (SH)

Department of Cancer Epidemiology, Division of Population Science, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Dr., MRC 213, Tampa, FL, 33612, USA.

Esther Azizi (E)

Department of Dermatology, Sheba Medical Center, Tel Hashomer, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Claudia Balestrini (C)

Servicio de Dermatología, Hospital Dr. Sótero del Río, Santiago de Chile, Chile.

D Timothy Bishop (DT)

Institute of Medical Research at St James's, University of Leeds, Leeds, UK.

William Bruno (W)

Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.

Blanca Carlos-Ortega (B)

Departamento de Ciencias Básicas, Escuela de Medicina Universidad de Monterrey, Monterrey, Mexico.

Francisco Cuellar (F)

Melanoma Unit, Dermatology Department, Hospital Clinic Barcelona, Institut de Investigacions biomediques August Pi Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Consejo Nacional de Ciencia y Tecnología (CONACYT), Ciudad de México, Mexico.

Anne E Cust (AE)

Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
Melanoma Institute Australia, The University of Sydney, Wollstonecraft, New South Wales, Australia.

David E Elder (DE)

Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.

Anne-Marie Gerdes (AM)

Department of Clinical Genetics, University Hospital of Copenhagen, Copenhagen, Denmark.

Paola Ghiorzo (P)

Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.
Genetics of Rare Cancers, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Thais C Grazziotin (TC)

Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, RS, Brazil.

Nelleke A Gruis (NA)

Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands.

Johan Hansson (J)

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Marko Hočevar (M)

Institute of Oncology Ljubljana, Ljubljana, Slovenia.

Veronica Höiom (V)

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Elizabeth A Holland (EA)

Westmead Institute for Medical Research, The University of Sydney, Westmead, New South Wales, Australia.

Christian Ingvar (C)

Departments of Clinical Sciences and Surgery, Lund University Hospital, Lund, Sweden.

Gilles Landman (G)

Department of Pathology, Escola Paulista de Medicina, UNIFESP, São Paulo, Brazil.
Department of Pathology, AC Camargo Cancer Center, São Paulo, Brazil.

Alejandra Larre-Borges (A)

Unidad de Lesiones Pigmentadas, Cátedra de Dermatología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay.

Graham J Mann (GJ)

Melanoma Institute Australia, The University of Sydney, Wollstonecraft, New South Wales, Australia.
Westmead Institute for Medical Research, The University of Sydney, Westmead, New South Wales, Australia.
John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia.

Montserrat Molgo (M)

Pontificia Universidad Católica de Chile, Santiago de Chile, Chile.

Luciana Facure Moredo (LF)

Skin Cancer Department, AC Camargo Cancer Center, São Paulo, Brazil.

Håkan Olsson (H)

Departments of Clinical Sciences and Surgery, Lund University Hospital, Lund, Sweden.

Jacoba J Out-Luiting (JJ)

Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands.

Barbara Perić (B)

Institute of Oncology Ljubljana, Ljubljana, Slovenia.

Dace Pjanova (D)

Latvian Biomedical Research and Study Centre, Riga, Latvia.

Susana Puig (S)

Melanoma Unit, Dermatology Department, Hospital Clinic Barcelona, Institut de Investigacions biomediques August Pi Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain.
Departament de Medicina, Universitat de Barcelona, Barcelona, Spain.

Julio Salas-Alanis (J)

Departamento de Ciencias Básicas, Escuela de Medicina Universidad de Monterrey, Monterrey, Mexico.
Dystrophic Epidermolysis Bullous Research Association Mexico, Monterrey, Mexico.

Helen Schmid (H)

Westmead Institute for Medical Research, The University of Sydney, Westmead, New South Wales, Australia.

Karin A W Wadt (KAW)

Department of Clinical Genetics, University Hospital of Copenhagen, Copenhagen, Denmark.

Julia A Newton-Bishop (JA)

Institute of Medical Research at St James's, University of Leeds, Leeds, UK.

Peter A Kanetsky (PA)

Department of Cancer Epidemiology, Division of Population Science, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Dr., MRC 213, Tampa, FL, 33612, USA. Peter.Kanetsky@moffitt.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH